Scholarlink

<p>Numerous aspects of depressive symptomatology in first-episode schizophrenia spectrum disorders (FES) remain unclear. Based on data from the FES OPTiMiSE trial, we estimated the prevalence of depression (Calgary Depression Scale for Schizophrenia (CDSS) total score ≥7) at baseline (<i>n</i> = 122, 27.5%) and at weeks 4 (<i>n</i> = 57, 15.9%) and 10 (<i>n</i> = 14, 21.5%). Baseline depression was cross-sectionally associated with more severe extrapyramidal symptoms (<i>p</i> = 0.036) and poorer subjective wellbeing (<i>p</i> &lt; 0.001). At week 4, baseline depression was linked to poorer psychosocial functioning (<i>p</i> &lt; 0.001) and subjective wellbeing (<i>p</i> &lt; 0.001). At week 10, baseline depression was associated with psychosis non-remission (<i>p</i> = 0.042) and worse subjective wellbeing (<i>p</i> = 0.011). There was a significant correlation between decrease in CDSS and PANSS total scores (<i>p</i> &lt; 0.001) at weeks 4 and 10. Depressive symptomatology in the FES OPTiMiSE trial was prevalent and associated with poorer objectively- and subjectively-measured outcomes over a 10-week follow-up. Early intervention for depression may improve outcomes in FES.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Depressive symptomatology in the first-episode schizophrenia spectrum disorders OPTiMiSE trial: prevalence, correlates, symptom progression and outcomes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月13日

查看全文
  • Javier-David Lopez-Morinigo,
  • David Fraguas,
  • Covadonga M. Diaz-Caneja,
  • Joaquin Galvañ,
  • Gregor Berger,
  • Stefan Leucht,
  • Inge Winter-van Rossum,
  • Celso Arango,
  • Carmen Moreno

摘要

Numerous aspects of depressive symptomatology in first-episode schizophrenia spectrum disorders (FES) remain unclear. Based on data from the FES OPTiMiSE trial, we estimated the prevalence of depression (Calgary Depression Scale for Schizophrenia (CDSS) total score ≥7) at baseline (n = 122, 27.5%) and at weeks 4 (n = 57, 15.9%) and 10 (n = 14, 21.5%). Baseline depression was cross-sectionally associated with more severe extrapyramidal symptoms (p = 0.036) and poorer subjective wellbeing (p < 0.001). At week 4, baseline depression was linked to poorer psychosocial functioning (p < 0.001) and subjective wellbeing (p < 0.001). At week 10, baseline depression was associated with psychosis non-remission (p = 0.042) and worse subjective wellbeing (p = 0.011). There was a significant correlation between decrease in CDSS and PANSS total scores (p < 0.001) at weeks 4 and 10. Depressive symptomatology in the FES OPTiMiSE trial was prevalent and associated with poorer objectively- and subjectively-measured outcomes over a 10-week follow-up. Early intervention for depression may improve outcomes in FES.